{
    "nct_id": "NCT00959881",
    "title": "Combined Administration Of Begacestat And Donepezil: A Multiple-Dose Study In Healthy Subjects",
    "status": "COMPLETED",
    "last_update_time": "2011-04-01",
    "description_brief": "This study examines the cardiac effects (effects on the heart) of administering donepezil and begacestat together to healthy subjects.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Begacestat (GSI-953) \u2014 selective \u03b3\u2011secretase inhibitor targeting APP cleavage / A\u03b2 production.",
        "Donepezil \u2014 acetylcholinesterase inhibitor (symptomatic cognitive enhancer)."
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests co\u2011administration of begacestat and donepezil. Begacestat is a small\u2011molecule \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 (disease pathology), which makes it a disease\u2011targeted small molecule. \ue200cite\ue202turn1search1\ue202turn1search6\ue201",
        "Act: I searched the literature to confirm drug identities and mechanisms. Begacestat (GSI\u2011953) is described as a selective, Notch\u2011sparing \u03b3\u2011secretase inhibitor that lowers A\u03b2 in preclinical models and showed pharmacodynamic effects on plasma A\u03b2 in early human studies. \ue200cite\ue202turn1search0\ue202turn1search1\ue201",
        "Act (continued): Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor used symptomatically to improve cognition in AD (a cognitive enhancer). \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Reflect: Because the trial includes a disease\u2011modifying small molecule (begacestat) together with a symptomatic cognitive enhancer (donepezil), the most appropriate single category from the provided list is 'disease-targeted small molecule' (begacestat). I note the trial is a cardiac safety study of the combination in healthy subjects, so the clinical goal here is safety/pharmacology rather than demonstrating cognitive benefit; nevertheless begacestat's mechanism places the trial under the disease\u2011targeted small molecule category. \ue200cite\ue202turn1search3\ue202turn0search1\ue201",
        "Web search results (key sources used): Begacestat \u2014 J Pharmacol Exp Ther / PubMed summary describing begacestat as a selective thiophene sulfonamide \u03b3\u2011secretase inhibitor that reduces A\u03b2 and showed PD in humans. \ue200cite\ue202turn1search1\ue202turn1search3\ue201; Begacestat background / ACS spotlight and product notes summarizing preclinical/human PD. \ue200cite\ue202turn1search0\ue202turn1search4\ue201; Donepezil \u2014 reviews and PubMed entries describing donepezil as a reversible acetylcholinesterase inhibitor used for symptomatic treatment of AD. \ue200cite\ue202turn0search5\ue202turn0search2\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial administers two drugs with distinct mechanisms \u2014 begacestat is a \u03b3\u2011secretase inhibitor developed to reduce production of amyloid\u2011\u03b2 (A\u03b2), a core disease pathology in AD, while donepezil is a reversible acetylcholinesterase inhibitor used as a symptomatic cholinergic cognitive enhancer. \ue200cite\ue202turn0search0\ue202turn1search0\ue201",
        "Act: Extracted details from the description and literature: begacestat (GSI\u2011953) selectively inhibits \u03b3\u2011secretase cleavage of APP and lowers A\u03b2 (preclinical and human PD evidence). \ue200cite\ue202turn0search2\ue202turn0search1\ue201 Donepezil is a centrally acting, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine and is used for symptomatic treatment of cognitive deficits in AD. \ue200cite\ue202turn1search7\ue202turn1search3\ue201 Because the intervention explicitly combines an amyloid\u2011lowering disease\u2011targeted small molecule with a symptomatic cholinergic agent, the trial addresses multiple, distinct CADRO targets (amyloid biology and neurotransmitter/cholinergic function).",
        "Reflect: The CADRO taxonomy maps begacestat to A) Amyloid beta and donepezil to D) Neurotransmitter Receptors (cholinergic/acetylcholine system). Since both are administered together in the same trial, the most accurate single-category assignment is R) Multi-target. If the user instead requires a single mechanistic label per drug, assign A) Amyloid beta to begacestat and D) Neurotransmitter Receptors to donepezil. Web sources used for these conclusions are cited above. \ue200cite\ue202turn0search0\ue202turn1search0\ue201"
    ]
}